Bio-Rad (BIO) Laboratories announced the launch of four new Droplet Digital PCR platforms, including its QX Continuum system and the QX700 series platforms acquired as part of its recent acquisition of Stilla Technologies. The expanded product portfolio, including over 400K assays, offers a comprehensive line of digital PCR products for life science research and diagnostic applications. Executive VP Jim Barry stated the launch strengthens Bio-Rad’s leadership in droplet digital PCR solutions.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO: